Lantern Pharma to Set Up AI Center of Excellence in Bengaluru to Scale RADR Platform

The center is designed to industrialize Lantern’s proprietary RADR® platform and support growing demand from pharmaceutical and academic partners worldwide.

Lantern Pharma Inc. announced the establishment of an artificial intelligence Center of Excellence and Advanced Agentic Labs in Bengaluru, India, marking a significant expansion of its global AI and computational drug development operations. 

The center is designed to industrialize Lantern’s proprietary RADR® platform and support growing demand from pharmaceutical and academic partners worldwide.

According to the company, the Bengaluru facility will serve as Lantern’s global scale-up hub, focusing on large-scale data engineering, development of machine learning-ready disease models, and integration with biopharma customers across multiple geographies. The initiative is expected to strengthen the company’s ability to deploy advanced AI modules through continuous, follow-the-sun development cycles.

Lantern said the new center will expand the technical capabilities of RADR®, which currently utilizes hundreds of billions of oncology-focused data points alongside curated disease models and machine learning algorithms. The center will also support the development of Lantern’s specialized large language models and large quantitative models used for molecular assessment, optimization, and generation across therapeutic areas.

The company plans to roll out the center in two phases. The first phase will focus on scaling AI-driven oncology programs, including multi-agentic systems for biomarker discovery, predictive modeling, and clinical trial optimization. Lantern stated that these capabilities build on its existing oncology pipeline, which includes three clinical-stage molecules and its CNS-focused subsidiary, Starlight Therapeutics.

The second phase will extend RADR® applications beyond oncology into areas such as inflammation, immunology, and neurodegenerative diseases. Lantern said this phase will support revenue-generating collaborations with biopharma companies in the United States, Europe, and Japan, while expanding disease-specific AI modules for conditions including lupus, rheumatoid arthritis, and Alzheimer’s disease.

Lantern confirmed that recruitment for AI engineers, data scientists, computational biologists, and machine learning specialists has already begun. The company expects the expansion and hiring to remain cash flow neutral, with initial operational impact anticipated during the first quarter of 2026.

The Bengaluru center will operate as a cloud-native development environment, supporting advanced model training, validation, and deployment. Lantern also plans to integrate the India-based team closely with its U.S. operations to accelerate development timelines.

Separately, the company announced it will host an Investor and Analyst Day in New York City on January 22, 2026, where it plans to demonstrate elements of the expanded RADR® platform and outline its AI industrialization roadmap.

Stay tuned for more such updates on Digital Health News